K. Fode

发表

Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma

R. Fisker, N. Marcussen, F. Donskov, 2004, Cancer Immunology, Immunotherapy.

A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma

H. Schmidt, L. Bastholt, H. Maase, 2002 .

Treatment of cervical disc disease using Cloward's technique the prognostic value of clinical preoperative data in 1,106 patients

E. Eriksen, J. Espersen, K. Fode, 2005, Acta Neurochirurgica.

Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial

H. Schmidt, I. Svane, G. Cook, 2010, Clinical Cancer Research.

Treatment of cervical disc disease using Cloward's technique

E. Eriksen, J. Espersen, K. Fode, 1987, Acta Neurochirurgica.

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

H. Schmidt, I. Svane, K. Fode, 2016, Oncoimmunology.

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.

G. Hermann, A. Petersen, F. Donskov, 2014, European journal of cancer.

Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.

M. Agerbaek, F. Donskov, K. Fode, 2013, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.

H. Schmidt, L. Bastholt, H. von der Maase, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Subcutaneous interleukin‐2 and interferon‐&agr; plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study

H. Schmidt, L. Bastholt, H. von der Maase, 2000, Melanoma research.

A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.

H. Schmidt, L. Bastholt, H. von der Maase, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Sudden death in mitral valve prolapse: associated accessory atrioventricular pathways.

P. Bjerregaard, A. Vesterby, M. Gregersen, 1982, Forensic science international.

Effect of Subcutaneous Human rleukin-21 in Patients with Metastatic Melanoma or R al Cell Carcinoma : A Phase I Trial

I. Svane, P. Selby, Janet E Brown, 2010 .

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.

H. Schmidt, M. Nishimura, J. J. Jensen, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.

G. Hermann, R. Ibsen, J. Kjellberg, 2015, European urology.

Spinal epidural hematomas

B. Dahlerup, K. Fode, J. Laursen, 1987, Clinical Neurology and Neurosurgery.

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.

O. S. Nielsen, S. Bentzen, T. Palshof, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylactic cranial irradiation in limited stage small cell lung cancer: survival benefit in patients with favourable characteristics.

O. S. Nielsen, S. Bentzen, T. Palshof, 1996, European journal of cancer.

Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanoma

J. Gehl, H. Schmidt, H. von der Maase, 2006, Cancer.

Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.

I. Christensen, H. Schmidt, H. von der Maase, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy

H. Schmidt, H. von der Maase, E. Nexo, 2005, Melanoma research.

A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2

I. Christensen, G. Hermann, A. Petersen, 2015, Acta oncologica.

Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma

N. Thatcher, H. von der Maase, M. Middleton, 2005, British Journal of Cancer.

Treatment of cervical disc disease using Cloward's technique

E. Eriksen, J. Espersen, K. Fode, 2005, Acta Neurochirurgica.

Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma.

I. Christensen, H. Schmidt, H. von der Maase, 2006, The Journal of investigative dermatology.

Treatment of cervical disc disease using Cloward's technique

E. Eriksen, J. Espersen, K. Fode, 1984, Acta Neurochirurgica.

The significance of preoperative radiological examinations in patients treated with Cloward's operation

E. Eriksen, O. F. Petersen, J. Espersen, 2005, Acta Neurochirurgica.

Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer.

H. von der Maase, M. Høyer, L. Fokdal, 2004, International journal of radiation oncology, biology, physics.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Interleukin-2 (IL-2)-based immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated between 1999 and 2008.

H. Schmidt, F. Donskov, M. Agerbæk, 2010 .

Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.

R. Ibsen, J. Kjellberg, F. Donskov, 2015, European urology.